6th International AIDS Conference


San Francisco, California, USA — June 20-23, 1990

Print this Article


Serum soluble CD8 molecule is a marker of immune activation and HIV pathogenesis.

Int Conf AIDS 1990 Jun 20-23; 6:336 (abstract no. 1090)
Nishanian P, Hofmann B, Liao D, Detels R, Fahey JL; UCLA Schools of Medicine and Public Health, L.A., California, USA

OBJECTIVE: To assay serum sCD8 levels and evaluate their significance in HIV-infected individuals.

METHODS: A sensitive and specific quantitative ELISA was developed to measure soluble CD8 in sera, using anti-CD8 monoclonal antibodies and the biotin-avidin system (Becton-Dickinson).

RESULTS: The level of serum sCD8 was low at 29.6 +/- 20.8 u/ml in normal controls (30), increased significantly to 44.6 +/- 22 u/ml in seronegative high-risk controls(49) and seroconverters (45) at 6 months before seroconversion (44 +/- 19.2), sharply increased, mean 65%, after seroconversion, and stayed at a plateau for the subsequent 2-3 years. The mean level for the asymptomatic seropositive group (66) was 70 +/- 27. sCD8 remained elevated in patients with AIDS (26), compared with seronegative controls. There was significant correlation between the level of sCD8 and CD4 and CD8 cell counts and ratio, serum neopterin and beta-2 microglobulin levels.

CONCLUSIONS: The results suggest that serum sCD8 levels reflect the activation of CD8 T cells in response to HIV infection. sCD8 is a marker of immune activation and HIV disease status.

Keywords: AEGIS, Antigens, CD8, Biological Markers, Acquired Immunodeficiency Syndrome, HIV Infections, Antigens, CD4, Neopterin, beta 2-Microglobulin, Human, ICA6KWDaegis,antigens,cd8,biologicalmarkers,acquiredimmunodeficiencysyndrome,hivinfections,antigens,cd4,neopterin,beta2-microglobulin,human,ica6

900620
1090

Copyright © 1990 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.